Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

featuring the Echo® Acoustic Technology
PUBLICATIONS

by scientists and researchers like you

103 Total Publications
HOME | RESOURCES | Publications

PUBLICATIONS

103 Total Publications

REFINE YOUR SEARCH



TITLES and AUTHORS Year Link PDF + Abstract
  • Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia A Eriksson, A Osterroos, S Hassan, J Gullbo, L Rickardson, M Jarvius, P Nygren, M Fryknas, R Larsson

    Institution: Department of Medical Sciences, Uppsala University

    Publication: Blood Cancer Journal, Nature

    2015 PDF abstract

    To find drugs suitable for repositioning for use against leukemia, samples from patients with chronic lymphocytic, acute myeloid and lymphocytic leukemias as well as peripheral blood mononuclear cells (PBMC) were tested in response to 1266 compounds from the LOPAC1280 library (Sigma). Twenty-five compounds were defined as hits with activity in all leukemia subgroups (o50% cell survival compared with control) at 10 μM drug concentration. Only one of these compounds, quinacrine, showed low activity in normal PBMCs and was therefore selected for further preclinical evaluation. Mining the NCI-60 and the NextBio databases demonstrated leukemia sensitivity and the ability of quinacrine to reverse myeloid leukemia gene expression. Mechanistic exploration was performed using the NextBio bioinformatic software using gene expression analysis of drug exposed acute myeloid leukemia cultures (HL-60) in the database. Analysis of gene enrichment and drug correlations revealed strong connections to ribosomal biogenesis nucleoli and translation initiation. The highest drug–drug correlation was to ellipticine, a known RNA polymerase I inhibitor. These results were validated by additional gene expression analysis performed in-house. Quinacrine induced early inhibition of protein synthesis supporting these predictions. The results suggest that quinacrine have repositioning potential for treatment of acute myeloid leukemia by targeting of ribosomal biogenesis.

    Publication / Type:
    Blood Cancer Journal, Nature
    Related Subject:
    screening, cancer, blood cancer, myeloid leukemia
  • Delivering an Automated and Integrated Approach to Combination Screening Using Acoustic-Droplet Technology Cross K, Craggs R, Swift D, Stiaram A, Daya S, Roberts M, Hawley S, Owen P, and Isherwood V

    Institution: AstraZeneca and Tessela plc.

    Publication: J Lab Autom. 2015 Apr 2. DOI: 10.1177/2211068215579163

    2015 PDF abstract

    Drug combination testing in the pharmaceutical industry has typically been driven by late-stage opportunistic strategies rather than by early testing to identify drug combinations for clinical investigation that may deliver improved efficacy. A rationale for combinations exists across a number of diseases in which pathway redundancy or resistance to therapeutics are evident. However, early assays are complicated by the absence of both assay formats representative of disease biology and robust infrastructure to screen drug combinations in a medium-throughput capacity. When applying drug combination testing studies, it may be difficult to translate a study design into the required well contents for assay plates because of the number of compounds and concentrations involved. Dispensing these plates increases in difficulty as the number of compounds and concentration points increase and compounds are subsequently rolled onto additional labware. We describe the development of a software tool, in conjunction with the use of acoustic droplet technology, as part of a compound management platform, which allows the design of an assay incorporating combinations of compounds. These enhancements to infrastructure facilitate the design and ordering of assay-ready compound combination plates and the processing of combinations data from high-content organotypic assays.

    Publication / Type:
    J Lab Autom. 2015 Apr 2. DOI: 10.1177/2211068215579163
    Related Subject:
    laboratory informatics, combinations, acoustic droplet technology, apothecary, assay-ready plate, high-content screening, sample management
  • Axitinib Effectively Inhibits BCR-ABL1(T315I) with a Distinct Binding Confirmation Pemovska T., Johnson E., Kontro M., Repasky G., Chen J., Wells P, Ciaran N., Cronin C., McTigue M.,

    Institution: Institute for Molecular Medicine Finland; University of Helsinki; La Jolla Laboratories, Pfizer

    Publication: Nature 519, 102-105 (March 5, 2015), doi:10.1038/nature14119

    2015 abstract

    The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30–50% of cases of adult acute lymphoblastic leukaemia1. Introduction of ABL1 kinase inhibitors (for example, imatinib) has markedly improved patient survival2, but acquired drug resistance remains a challenge3, 4, 5. Point mutations in the ABL1 kinase domain weaken inhibitor binding6 and represent the most common clinical resistance mechanism...

    Publication / Type:
    Nature 519, 102-105 (March 5, 2015), doi:10.1038/nature14119
    Related Subject:
    Translational research, oncogene
    Link:
    http://eorder.sheridan.com/3_0/display/index.php?flashprint=4698
  • Delivering an Automated and Integrated Approach to Combination Screening Using Acoustic-Droplet Technology K Cross, R Craggs, D Swift, A Sitaram, S Daya, M Roberts, S Hawley, P Owen, B Isherwood

    Institution: Discovery Sciences, AstraZeneca R&D, Macclesfield, UK

    Publication: Journal of Laboratory Automation (JALA)

    2015 abstract

    Drug combination testing in the pharmaceutical industry has typically been driven by late-stage opportunistic strategies rather than by early testing to identify drug combinations for clinical investigation that may deliver improved efficacy. A rationale for combinations exists across a number of diseases in which pathway redundancy or resistance to therapeutics are evident. However, early assays are complicated by the absence of both assay formats representative of disease biology and robust infrastructure to screen drug combinations in a medium-throughput capacity. When applying drug combination testing studies, it may be difficult to translate a study design into the required well contents for assay plates because of the number of compounds and concentrations involved. Dispensing these plates increases in difficulty as the number of compounds and concentration points increase and compounds are subsequently rolled onto additional labware. We describe the development of a software tool, in conjunction with the use of acoustic droplet technology, as part of a compound management platform, which allows the design of an assay incorporating combinations of compounds. These enhancements to infrastructure facilitate the design and ordering of assay-ready compound combination plates and the processing of combinations data from high-content organotypic assays.

    Publication / Type:
    Journal of Laboratory Automation (JALA)
    Related Subject:
    laboratory informatics, combinations, acoustic droplet technology, apothecary, assay-ready plate, high-content screening, sample management
    Link:
    http://jla.sagepub.com/content/21/1/143.full.pdf+html
  • Identification of b-hematin inhibitors in the MMV Malaria Box Fong K., Sandlin R. and Wright D.

    Institution: Vanderbilt University

    Publication: International Journal for Parasitology: Drugs and Drug Resistance, Volume 5, Issue 3, December 2015

    2015 abstract

    The Malaria Box, assembled by the Medicines for Malaria Venture, is a set of 400 structurally diverse, commercially available compounds with demonstrated activity against blood-stage Plasmodium falciparum. The compounds are a representative subset of the 20,000 in vitro antimalarials identified from the high-throughput screening efforts of St. Jude Children's Research Hospital (TN, USA), Novartis and GlaxoSmithKline. In addition, a small set of active compounds from commercially available libraries was added to this group, but it has not previously been published. Elucidation of the biochemical pathways on which these compounds act is a major challenge; therefore, access to these compounds has been made available free of charge to the investigator community. Here, the Malaria Box compounds were tested for activity against the formation of b-hematin, a synthetic form of the heme detoxification biomineral, hemozoin. Further, the mechanism of action of these compounds within the malaria parasite was explored. Ten of the Malaria Box compounds demonstrated significant inhibition of b-hematin formation. In this assay, doseeresponse data revealed IC50 values ranging from 8.7 to 22.7 mM for these hits, each of which is more potent than chloroquine (a known inhibitor of hemozoin formation). The in vitro antimalarial activity of these ten hits was confirmed in cultures of the chloroquine sensitive D6 strain of the parasite resulting in IC50 values of 135e2165 nM, followed by testing in the multidrug resistant strain, C235. Cultures of P. falciparum (D6) were then examined for their heme distribution following treatment with nine of the commercially available confirmed compounds, seven of which disrupted the hemozoin pathway.

    Publication / Type:
    International Journal for Parasitology: Drugs and Drug Resistance, Volume 5, Issue 3, December 2015
    Related Subject:
    b-hematin inhibitors, MMV malaria
    Link:
    http://www.sciencedirect.com/science/article/pii/S2211320715000111
  • A Personalised Medicine Drug Sensitivity and Resistance Testing Platform and Utilisation of Acoustic Droplet Ejection at the Institute for Molecular Medicine Finland Saarela J, Kulesskiy E, Laamanen K, Pemovska T, Pietiainen V, Potdar S, von Schantz-Fant C, Turunen

    Institution: Institute for Molecular Medicine Finland, University of Helsinki, Finland (FIMM)

    Publication: Synergy Vol 1, Issue 1, Sep 2014, Pages 78 doi:10.1016/j.synres.2014.07.001

    2015 abstract

    The High Throughput Biomedicine (HTB) unit at FIMM Technology Centre provides a wide range of biomedical high throughput assays. In collaboration with research groups and the Hospital District of Helsinki and Uusimaa, we have set up drug sensitivity and resistance testing (DSRT) platform with a set of 450 approved and investigational oncology drugs on patient samples. Ex vivo drug testing is currently performed at FIMM with primary cancer cells from patients with leukaemia and multiple myeloma as well as cancer cell lines and the drug sensitivity responses are integrated with molecular profiling such as exome sequencing, transcriptomics and phosphoproteomics. Currently, DSRT is run in 384-well plate format in 5 concentrations for each drug or in 1536-well plate format with 9 concentrations per drug and the assay plates are pre-drugged using acoustic droplet ejection with Labcyte® Echo® 550. The viability and cell death of cells is measured after 72 h and results are analysed using Dotmatics Studies – software and an in-house developed interface, Breeze. Application of the platform to AML patient samples has uncovered taxonomic drug-response subtypes and individualised therapy based on DSRT has resulted in several clinical responses. The DSRT platform enables drug repositioning, provides new combinatorial possibilities and allows for linking drug sensitivities to predictive biomarkers. We are developing the platform with additional readouts and increasing the number of drugs. Our Labcyte Access Workstation, with Echo 550 and Echo® 525 integration, allows development and set-up of miniaturised follow-up assays, such as reverse-phase protein array and qPCR, using non-contact acoustic dispensing. 

    Publication / Type:
    Synergy Vol 1, Issue 1, Sep 2014, Pages 78 doi:10.1016/j.synres.2014.07.001
    Related Subject:
    Medicine Drug Sensitivity Resistance Testing Platform Utilisation Acoustic Droplet Ejection Institute of Molecular Medicine Finland
    Link:
    http://www.sciencedirect.com/science/article/pii/S2213713014000029
  • Quantitative Analysis of Long-Form Aromatase mRNA in the Male and Female Rat Brain Tabatadze N, Sato S and Woolley C

    Institution: Northwestern University

    Publication: PLoS ONE

    2014 abstract

    In vitro studies show that estrogens acutely modulate synaptic function in both sexes. These acute effects may be mediated in vivo by estrogens synthesized within the brain, which could fluctuate more rapidly than circulating estrogens. For this to be the case, brain regions that respond acutely to estrogens should be capable of synthesizing them. To investigate this question, we used quantitative real-time PCR to measure expression of mRNA for the estrogen-synthesizing enzyme, aromatase, in different brain regions of male and female rats. Importantly, because brain aromatase exists in two forms, a long form with aromatase activity and a short form with unknown function, we targeted a sequence found exclusively in long-form aromatase. With this approach, we found highest expression of aromatase mRNA in the amygdala followed closely by the bed nucleus of the stria terminalis (BNST) and preoptic area (POA); we found moderate levels of aromatase mRNA in the dorsal hippocampus and cingulate cortex; and aromatase mRNA was detectable in brainstem and cerebellum, but levels were very low. In the amygdala, gonadal/hormonal status regulated aromatase expression in both sexes; in the BNST and POA, castration of males down-regulated aromatase, whereas there was no effect of estradiol in ovariectomized females. In the dorsal hippocampus and cingulate cortex, there were no differences in aromatase levels between males and females or effects of gonadal/hormonal status. These findings demonstrate that long-form aromatase is expressed in brain regions that respond acutely to estrogens, such as the dorsal hippocampus, and that gonadal/hormonal regulation of aromatase differs among different brain regions.

    Publication / Type:
    PLoS ONE
    Related Subject:
    Quantitative Analysis Long-Form Aromatase mRNA Male Female Rat Brain
    Link:
    http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0100628
  • Quantitative Scoring of Differential Drug Sensitivity for Individually Optimized Anticancer Therapies Bhagwan Y., Pemovska T., Szwajda A., Kulesskiy E., Kontro M., Karjalainen R., Majumder M., Malani D.

    Institution: Institute for Molecular Medicine Finland (FIMM), University of Helsinki; Hematology Research Unit, H

    Publication: Scientific Reports 4, Article number: 5193; doi: 10.1038/srep05193 Subject terms: predictive medicin

    2014 abstract

    We developed a systematic algorithmic solution for quantitative drug sensitivity scoring (DSS), based on continuous modeling and integration of multiple dose-response relationships in high-throughput compound testing studies. Mathematical model estimation and continuous interpolation makes the scoring approach robust against sources of technical variability and widely applicable to various experimental settings, both in cancer cell line models and primary patient-derived cells. Here, we demonstrate its improved performance over other response parameters especially in a leukemia patient case study, where differential DSS between patient and control cells enabled identification of both cancer-selective drugs and drug-sensitive patient sub-groups, as well as dynamic monitoring of the response patterns and oncogenic driver signals during cancer progression and relapse in individual patient cells ex vivo. An open-source and easily extendable implementation of the DSS calculation is made freely available to support its tailored application to translating drug sensitivity testing results into clinically actionable treatment options.

    Publication / Type:
    Scientific Reports 4, Article number: 5193; doi: 10.1038/srep05193 Subject terms: predictive medicin
    Related Subject:
    Quantitative Scoring Drug Sensitivity Anticancer Therapies
    Link:
    http://www.nature.com/srep/2014/140605/srep05193/full/srep05193.html?message-global=remove
  • Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias Kang J, et al

    Institution: Sanford-Burnham Medical Research Institute, La Jolla, California

    Publication: PLoS ONE 9(7): e102221. doi:10.1371/journal.pone.0102221

    2014 abstract

    The BCR-ABL translocation is found in chronic myeloid leukemia (CML) and in Ph+ acute lymphoblastic leukemia (ALL) patients. Although imatinib and its analogues have been used as front-line therapy to target this mutation and control the disease for over a decade, resistance to the therapy is still observed and most patients are not cured but need to continue the therapy indefinitely. It is therefore of great importance to find new therapies, possibly as drug combinations, which can overcome drug resistance. In this study, we identified eleven candidate anti-leukemic drugs that might be combined with imatinib, using three approaches: a kinase inhibitor library screen, a gene expression correlation analysis, and literature analysis. We then used an experimental search algorithm to efficiently explore the large space of possible drug and dose combinations and identified drug combinations that selectively kill a BCR-ABL+ leukemic cell line (K562) over a normal fibroblast cell line (IMR-90). Only six iterations of the algorithm were needed to identify very selective drug combinations.The efficacy of the top forty-nine combinations was further confirmed using Ph+ and Ph- ALL patient cells, including imatinib-resistant cells. Collectively, the drug combinations and methods we describe might be a first step towards more effective interventions for leukemia patients, especially those with the BCR-ABL translocation.

    Publication / Type:
    PLoS ONE 9(7): e102221. doi:10.1371/journal.pone.0102221
    Related Subject:
    Identification Drug Combinations Imatinib Treatment BCR-ABL+ Leukemias
    Link:
    http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0102221
  • The High Throughput Biomedicine Unit at the Institute for Molecular Medicine Finland: High Throughput Screening Meets Precision Medicine Pietiainen V, Saarela J, von Schantz C, Turunen L, Ostling P and Wennerberg K

    Institution: Institute for Molecular Medicine Finland, University of Helsinki, Finland (FIMM)

    Publication: Combinatorial Chemistry & High Throughput Screening, Volume 17, Number 4, May 2014, pp. 377-386(10)

    2014 abstract

    The High Throughput Biomedicine (HTB) unit at the Institute for Molecular Medicine Finland FIMM was established in 2010 to serve as a national and international academic screening unit providing access to state of the art instrumentation for chemical and RNAi-based high throughput screening. The initial focus of the unit was multiwell plate based chemical screening and high content microarray-based siRNA screening. However, over the first four years of operation, the unit has moved to a more flexible service platform where both chemical and siRNA screening is performed at different scales primarily in multiwell plate-based assays with a wide range of readout possibilities with a focus on ultraminiaturization to allow for affordable screening for the academic users. In addition to high throughput screening, the equipment of the unit is also used to support miniaturized, multiplexed and high throughput applications for other types of research such as genomics, sequencing and biobanking operations. Importantly, with the translational research goals at FIMM, an increasing part of the operations at the HTB unit is being focused on high throughput systems biological platforms for functional profiling of patient cells in personalized and precision medicine projects.

    Publication / Type:
    Combinatorial Chemistry & High Throughput Screening, Volume 17, Number 4, May 2014, pp. 377-386(10)
    Related Subject:
    High Throughput Biomedicine Unit Institute for Molecular Medicine Finland High Throughput Screening Medicine
    Link:
    http://www.ingentaconnect.com/content/ben/cchts/2014/00000017/00000004/art00010
EXPAND ABSTRACTS




Featured Labcyte Downloads
For Research Use Only Not for use in Diagnostics
TOP